Q-omics provides the consensus-scored DLEC1 profile across patient tissues and cancer cell-line models. DLEC1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, DLEC1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, DLEC1 RNA expression shows 18,265 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where DLEC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DLEC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DLEC1 survival associations across molecular data types. DLEC1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DLEC1 RNA expression–survival associations across cancer types. High DLEC1 expression shows unfavorable associations in KIRC and LGG, but favorable associations in HNSC, BLCA, MESO and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for DLEC1 RNA expression.
This table summarizes DLEC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DLEC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DLEC1 shows lower tumor expression in KIRC, KICH, LUAD, LUSC, BRCA and COAD. The KIRC box plot shows higher DLEC1 RNA expression in normal versus tumor tissue (log2 FC = −0.205, t-test p < 0.001).
This table shows molecular features associated with DLEC1 in patient tissues and cancer cell lines. In patient samples, DLEC1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DLEC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
